Convergent Therapeutics, Inc.
Jillian Curiale is an accomplished finance professional with extensive experience in financial management and operations. Currently serving as Director of Finance at Convergent Therapeutics, Inc. since September 2023, Jillian previously held the position of Director of Finance and Operations at The NemetzGroup LLC. Jillian's tenure at Oncorus included roles as Associate Director of Finance and Senior Accounting Manager from May 2017 to March 2023. Prior to that, Jillian was the Accounting Manager at Merrimack, where recognition as the 2015 Merrimack Leadership Award Winner was achieved. Earlier career roles include Senior Staff Accountant, Staff Accountant, and Accounts Payable Accountant at NaviNet. Educational qualifications include an MBA in Accounting and Finance from Northeastern University and a BSBA in Business Administration from Suffolk University.
This person is not in any teams
Convergent Therapeutics, Inc.
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.